Monetization Path 1 · Population Mental Health
Flourish for the Sub-Clinical Majority
The Flourish app deployed as a population-level mental health tool for the sub-clinical majority — people experiencing everyday stress, anxiety, and low mood who are not in active treatment. Also serves as a scalable solution for step-down care after crisis or treatment. Institutional onboarding is provided, and organizational resources are integrated into the AI for local resource navigation. Buyers are population-health administrators: health plans (PMPM), higher education institutions (PMPY per student), and EAP administrators.
TAM
$9.5B
Key Product Features
On top of the Flourish app (B2C / consumer version), includes organizational customization:
Institutional onboarding & SSO
Org resources integrated into AI (local navigation)
Population wellbeing & engagement dashboard
Org-specific crisis handling protocol
Why this market, why now — population wellness
Payer cost explosion
20%
UnitedHealthcare is spending 20% more on behavioral health care year-over-year — roughly 3× the normal rate of healthcare inflation. CEO Tim Noel called it an “unanticipated acceleration” (Q2 2025); UHC’s quarterly operating profit fell from $4.0B to $2.1B as a result. Centene named behavioral health the biggest driver of its cost increases in the same period. 1 in 3 health plan actuaries now names behavioral health a top-3 cost inflator. Employers are projecting a median 10% increase in total healthcare costs for 2026 — behavioral health is running at double that. Payers are urgently looking for tools that slow this down.
Current models aren’t scalable
3×
UnitedHealth Group’s CMO: therapy-for-all at current rates would triple insurance premiums. An independent 2025 study found that self-guided digital wellness tools (Headspace, Talkspace, Teladoc and others) reduce payer spending by $3.6M per year per million members — while blended-care incumbents (Lyra Health, Spring Health, Modern Health) raise costs by $25.6M per million members. These self-guided tools are basic content libraries and CBT video modules. With multiple RCTs, superior user experience, and 40+ interactive AI features, Flourish holds promise of significantly outperforming that baseline in cost savings. Payers want population-priced tools — Flourish’s PMPM model is exactly what they’re asking for.
Higher ed — massive unmet need
63%
63% of students report needing mental health support, yet only 38% received counseling or therapy in the past year (Healthy Minds Study 2024–25, N=84,735). 45% screen positive for depression or anxiety. 11% seriously considered suicide. The financial stakes are direct: student dropouts cost institutions $16B per year in lost tuition, and 57% of students who stopped out (left college without completing) cite mental health as the reason (Hope Center 2023–24, N=74,350). For universities, investing in mental health is a retention strategy.
EAPs face the same capacity wall
82%
82% of US employers offer EAPs (SHRM 2024), yet median utilization sits at just 5.5% — not because demand is low, but because EAPs are structured for clinical intervention, not everyday support. Research shows 24% of employees need counseling, but only ~1% need clinical-level care. The other 23% are the sub-clinical majority — stressed, anxious, not in crisis — who need a sub-clinical tool exactly like Flourish. 65% of employees report feeling as or more stressed than five years ago (Forrester/Spring Health 2025), and mental health is now the leading cause of long-term sick leave globally.
Market Size Estimate
Segment 1 — U.S. Managed Care (Health Plans)
$9.3B TAM
| Plan Type | Covered Lives | PMPM | Annual TAM |
|---|---|---|---|
| Commercial / Employer-Sponsored (ESI) | 165M | $3.00 | $5.9B |
| Medicare Advantage | 33.4M | $3.00 | $1.2B |
| Medicaid Managed Care | 72M | $1.50 | $1.3B |
| ACA Marketplace (individual / Obamacare plans) | 24M | $3.00 | $0.9B |
| Health Plans Total | 294M | — | $9.3B |
Pricing model: $3 PMPM on the full covered population — standard for population wellness tools. Payers pay per member regardless of utilization, mirroring how EAP and disease management programs are contracted. Flourish’s $3 PMPM demonstrates 10.9:1 ROI for payers — a business case that sells itself. Active pipeline: BCBS RI, Aetna, Carelon, Horizon BCBS NJ, BCBS SC. Sales cycle: 8–12 months. Carelon is an EAP — so one health plan deal opens two contract vehicles into the same covered population: a health plan PMPM and a separate EAP per-member fee. Both charge on the same lives but flow through different budget lines and procurement owners, making them additive revenue rather than double-counting.
Segment 2 — Higher Education
$179M TAM
| Type | Students | PMPY | TAM |
|---|---|---|---|
| 4-Year Universities | 14.4M | $8 | $115M |
| Community Colleges | 4.8M | $8 | $38M |
| Graduate Programs | 3.2M | $8 | $26M |
| Total | 22.4M | $8 | $179M |
Fastest-closing channel (months) with a repeatable, scalable playbook. 6 contracts and growing — multi-year (Jackson College, Singapore Management University), single year now 1st renewing (Villanova, UCNJ), single year now 2nd renewal (Foothill), substantial paid pilot (UC Berkeley, $250K first year). Built a pipeline of 200+ leads through national conferences. Exploring new partnership with JED Foundation (500+ campus coverage). Pricing note: $3–12 PMPY based on total enrolled students — same model as student health fees — unless otherwise negotiated. Eliminates utilization risk for Flourish.
Competitor Spotlight — Population Wellness
Primary competitor
Headspace (Headspace Health / Ginger)
The most direct incumbent in B2B wellness — sells to health plans and employers at PMPM, now deployed by over 2,000 employers. Recently launched Ebb, an AI companion for self-reflection. However, Headspace’s core product remains content and meditation-based with limited clinical depth, and its evidence base has significant limitations: Ebb has no RCT evidence, and prior Headspace studies used small, non-clinical samples with modest effect sizes.
Emerging / watch
Ash by Slingshot AI
Ash launched in July 2025 originally positioned as an “AI therapist” — framing that generated significant public pushback, which has since led the company to soften its positioning. Go-to-market remains firmly D2C with no clear B2B population-health channel. Its published safety data has been publicly questioned by independent experts, and the company has lobbied the FDA to soften scrutiny of “general wellness apps” — a positioning that creates procurement risk for institutional buyers.
Flourish’s advantage
Clinical evidence Multiple large-scale RCTs currently under peer review in top journals.
Safety VERA-MH is the only open-source behavioral health AI safety benchmark; Flourish ranks highest across models.
Product experience Flourish is a continuous, AI-native, evidence-based mental health companion with 40+ AI features — from in-the-moment emotional support to long-term habit building — making it the all-in-one longitudinal support. Rated 4.9+ on the App Store and Google Play across 2,200+ ratings. Winner of the International Positive Psychology Association 2026 Tech for Human Flourishing Award, Stanford Center for Accelerated Learning AI + Create Award (selected from 300+ candidates), and nominated for the 2026 Webby Award.
Monetization Path 2 · Clinical Integration · In Active Treatment
Clinical Workflow Integration as the Therapy Companion
The Flourish app paired with a clinician-facing dashboard (session-ready insights, PHQ-9/GAD-7 trends, crisis alerts, homework tracking) and EHR API integration. Sold to provider organizations for patients actively undergoing mental health treatment — or on waitlists prior to intake. Supports measurement-based care between sessions and serves as a scalable waitlist management solution.
TAM
$7–12.6B
Key Product Features
On top of the organizationally customized Flourish app (Path 1 version), includes clinical workflow integration:
EHR integration via API (Epic, Cerner, SimplePractice)
Clinician-facing dashboard (case management)
Clinical escalation pathway
Emergency notification system
Reimbursement pathways & why now
What is RTM? Remote Therapeutic Monitoring (RTM) is a set of Medicare and commercial insurance billing codes that allow healthcare providers to bill insurance for digitally monitoring patients between therapy sessions. The codes (CPT codes, meaning standardized billing codes used across US healthcare) reimburse providers monthly for reviewing patient data and managing care plans remotely. For Flourish, this means a therapist or psychiatrist can bill insurance for the time they spend reviewing a patient’s Flourish data.
RTM reimbursement — live now
2022
RTM codes (98978, 98980, 98981) are reimbursable today — no FDA clearance needed. AMA removed the 16-day data threshold, effective Jan 2026. Behavioral health providers can bill insurance monthly for monitoring Flourish data, See reimbursement breakdown below.
FDA TEMPO + CMS ACCESS
2026
December 2025: FDA and CMS jointly opened a landmark pathway for AI-enabled behavioral health tools covering depression and anxiety — with outcome-based reimbursement and enforcement discretion for evidence-generating devices. Flourish has submitted a statement of interest.
Reimbursement Economics
RTM Economics — What the Provider Bills Insurance Per Patient
~$110/patient/mo (base RTM stack)
CPT 98975 — Initial Setup (one-time)
~$20
Patient onboarding and education. Billed once per episode of care. AMA removed 16-day threshold effective Jan 2026.
CPT 98978 — CBT Data Transmission (monthly)
~$20/mo
Monthly device supply code specific to cognitive behavioral therapy data. Covers Flourish’s data transmission to the provider. Billed alongside 98980/98981.
CPT 98980 — Treatment Mgmt (first 20 min/mo)
~$50/mo
Provider bills monthly for reviewing Sunnie data and managing care plan. This single code alone covers Flourish’s $30/mo base fee entirely.
CPT 98981 — Treatment Mgmt (add-on 20 min)
~$40/mo
Add-on to 98980 for each additional 20 minutes. Dashboard tracks time spent for billing compliance.
Full RTM stack per patient per month (98978 + 98980 + 98981)
Flourish charges $25–40/mo · Provider nets $70–85/mo from RTM billing after Flourish fee · Self-funding from month one
~$110 / mo
The RTM pitch is self-funding from day one. A group practice with 100 RTM-enabled patients bills ~$108K/year from 98980 alone — more than covering Flourish’s fee ($36K/year). Adding 98978 + 98981 brings total billable to ~$132K/year for the same 100 patients, with the provider netting $72K–$96K/year after Flourish’s fee.
Proven analog — physical therapy led the way. RTM billing was first adopted at scale in musculoskeletal care. Platforms like Medbridge and Limber Health built profitable SaaS businesses on exactly this model — platform fee plus RTM reimbursement that more than covers the cost. Behavioral health RTM is 3–4 years behind MSK on this adoption curve, with the CBT-specific code (98978) only recently established. Flourish is positioned to own this white space: the first mental health companion with end-to-end RTM billing infrastructure built in.
Proven analog — physical therapy led the way. RTM billing was first adopted at scale in musculoskeletal care. Platforms like Medbridge and Limber Health built profitable SaaS businesses on exactly this model — platform fee plus RTM reimbursement that more than covers the cost. Behavioral health RTM is 3–4 years behind MSK on this adoption curve, with the CBT-specific code (98978) only recently established. Flourish is positioned to own this white space: the first mental health companion with end-to-end RTM billing infrastructure built in.
Market Size Estimate
Provider Segments — Bottoms-Up TAM
$7.0B – $12.6B TAM
| Provider Type | Active BH Patients | Platform Fee | TAM (no RTM) | TAM (w/ RTM) | Notes |
|---|---|---|---|---|---|
| VA / Federal (DoD, TRICARE) | ~1.5M | $30/mo | $540M | $990M | ~550K veterans received VA mental health treatment in FY2023 + ~150K DoD/TRICARE. Largest single-payer behavioral health system in the US. Ties directly to our BAA 36C10X24R0053 grant submission targeting post-crisis and in-between session care. |
| Academic Medical Centers & Health Systems | ~2.0M | $40/mo | $960M | $1.56B | McLean Hospital, Johns Hopkins, UCSF, NYU Langone. Epic/Cerner integration. |
| FQHCs — Federally Qualified Health Centers (1,400+ community clinics) | ~2.5M | $25/mo | $750M | $1.50B | Federally funded community clinics serving underserved populations. Medicaid-heavy. RTM billing directly diversifies FQHC revenue. |
| Community Mental Health Centers (3,000+) | ~3.0M | $25/mo | $900M | $1.80B | State-funded; high Medicaid volume. Strong RTM revenue incentive. |
| Group Private Practices — multi-clinician therapy & psychiatry practices | ~5.0M | $30/mo | $1.80B | $3.30B | Largest segment. Typically 2–20 therapists under one entity. SimplePractice integration. RTM billing fully covers platform fee — zero net cost to the practice. |
| Integrated Health Systems | ~3.0M | $35/mo | $1.26B | $2.16B | Kaiser Permanente, Geisinger, Intermountain, Mass General Brigham. Epic integration standard. |
| University Counseling Centers | ~0.5M | $30/mo | $180M | $330M | Natural upsell from population wellness channel. Counselors already know the Flourish app. Can be used to validate clinical integration. |
| Telehealth Behavioral Health Platforms | ~2.0M | $20/mo | $480M | $960M | Talkspace (UHS), Brightside, Cerebral, Alma. Platform integration / white-label. |
| Total — All Provider Segments | ~19.5M patients | $25–40/mo | $6.87B | $12.60B | Bottoms-up · TAM (w/ RTM) assumes 98978 + 98980 at minimum; 98981 is additional upside · 12-month annual basis |
Why bottoms-up is more conservative than top-down: SAMHSA 2023 shows ~26M US adults received therapy in the past year. The provider-segment approach uses ~19.5M — excluding self-pay therapists. The $7B TAM is the more defensible number for investor conversations.
Provider Pipeline — Entry Points by Type
VA / Federal (BAA 36C10X24R0053)
Post-crisis care; grant-funded; federal scale
University counseling centers
Wellness channel upsell → clinical integration; Villanova, SMU path
Academic Medical Centers (McLean, etc.)
Reference site; Epic integration; downstream influence
Health plan provider networks (Carelon, Optum)
Deploy as MBC tool across network therapists
Group private practices — direct EHR integration
SimplePractice; RTM as primary value prop
FQHCs / Community mental health centers
High-volume Medicaid; RTM billing diversifies revenue
Telehealth behavioral health platforms
Platform integration / white-label; high-volume channel
Competitor Spotlight — Clinical Integration
US competitors
Headspace Health / Jimini Health
Headspace is extending its B2B platform into provider-adjacent settings but lacks a clinician dashboard and RTM infrastructure. Jimini Health ($25M raised, including a $17M seed round in March 2026 led by M13) is building Sage, a clinician-supervised AI companion deployed at large behavioral health organizations — where partner clinicians, not Jimini staff, supervise every patient interaction. The most direct clinical integration analog. Jimini lacks Flourish’s published RCT evidence and open safety framework, and has no B2C channel or population wellness offering.
International competitor
Limbic AI (UK)
A UK-based AI mental health platform ($14M raised, Series A led by Khosla Ventures) deployed across NHS talking therapies (IAPT/IAPTS). Limbic has CE-marked regulatory status and has published peer-reviewed research on the quality of AI-delivered CBT responses — but lacks RCT evidence on patient clinical outcomes such as symptom reduction. Flourish’s evidence base is at the outcome level. Limbic’s focus is primarily UK/European public health with limited US penetration; Flourish’s US regulatory positioning (TEMPO) and RTM billing infrastructure are key differentiators.
Monetization Path 3 · Emerging · Contingent on TEMPO Selection
Prescription Digital Therapeutic — Outcome-Based Reimbursement
In March 2026, Flourish submitted to the FDA’s TEMPO pilot. If selected, Flourish could be prescribed by clinicians and reimbursed by Medicare under the CMS ACCESS model based on measurable patient outcomes — shifting from activity-based billing (RTM) to outcome-aligned payment.
What TEMPO selection means for Flourish
~10
FDA selects up to ~10 manufacturers per clinical area for the TEMPO pilot. Selected companies receive enforcement discretion on premarket authorization requirements while collecting real-world outcome data — turning clinical deployment into an FDA evidence-generation pathway. The same RCT evidence base and VERA-MH safety framework that differentiate Flourish in Paths 1 and 2 are the primary selection criteria. Under the CMS ACCESS model, Outcome-Aligned Payments (OAPs) are tied directly to measurable clinical improvement (e.g. PHQ-9 reduction for depression, GAD-7 for anxiety) — not clinician time. Patient co-pays are also waived under ACCESS, removing a major adoption barrier.
Comparison: Path 2 vs. Path 3
| Dimension | Path 2 — RTM (Today) | Path 3 — TEMPO/ACCESS (2026–27) |
|---|---|---|
| Reimbursement basis | Clinician time reviewing data | Measurable patient outcome improvement |
| FDA clearance required | No | No (enforcement discretion under TEMPO) |
| Who pays | Medicare + commercial insurance (per code) | CMS Medicare Part B (outcome-aligned) |
| Patient co-pay | Standard cost-sharing applies | Waived under ACCESS model |
| Revenue model for Flourish | Platform fee + RTM revenue share | Revenue share on Outcome-Aligned Payments |
| Price point | $25–40/mo platform fee | Higher — tied to demonstrated outcomes |
| Evidence required | Safety; RTM documentation | RCT evidence of efficacy + safety framework |
| Status | Live — billable today | Emerging — TEMPO selection pending |
Why this matters: Outcome-based reimbursement is the highest-value commercial model in digital health — and the hardest to achieve without clinical evidence. Flourish’s RCT portfolio and VERA-MH safety benchmark are precisely the assets FDA and CMS require for TEMPO participation. Path 2 generates the real-world evidence; Path 3 monetizes it at a premium. If selected, Flourish would be among the first ~10 behavioral health AI companies in the US operating under this framework.
Combined TAM · Both Channels
$17–22B
Population wellness channel $9.5B + clinical integration channel $7B–$12.6B depending on RTM adoption. No channel conflict — payers and institutions buy population wellness; provider organizations buy clinical integration. Path 3 (TEMPO/ACCESS) represents additional upside not included in this figure.
SAM · Serviceable Addressable
~$3–4B
Path 1: tech-forward health plans + higher education institutions + EAP via plan deals. Path 2: VA, university counseling centers, group practices in target markets. Pilots expand to full populations: a single university system or health plan network can multiply initial contract value 5–20× on renewal.
SOM · 3-Year Obtainable
$15–40M ARR
Higher ed PMF (50–100 universities at $3–12 PMPY) + one health plan deal or VA/KP anchor. Path 2 (provider integration) and Path 3 (TEMPO) are parallel tracks where we are building infrastructure and evidence, not yet at commercial scale.
Sources: UnitedHealth Group Q2 2025 earnings; BH Business July 2025; PHTI 2025 Assessment: Virtual Solutions for Depression & Anxiety; SAMHSA 2023 NSDUH; CDC NHIS 2023; Healthy Minds Network 2024–25 (N=84,735); Hope Center 2023–24 (N=74,350); SHRM 2024 Employee Benefits Survey; Forrester/Spring Health Workforce Mental Health 2025; Calm Health EAP utilization research 2025; PwC Behind the Numbers 2026; KFF 2024; VA Annual Report FY2023; HRSA FQHC data; RTM: CMS 2026 Physician Fee Schedule Final Rule; AMA CPT Editorial Panel Jan 2026 (16-day threshold removal; 98978 CBT code); FDA TEMPO Pilot Federal Register Dec 2025; CMS ACCESS Model Dec 2025; Medbridge & Limber Health RTM platform documentation 2025–26; Jimini Health funding announcement March 2026 (STAT News, MedCity News); Limbic AI Series A announcement March 2024 (BusinessWire, $14M, Khosla Ventures); Limbic AI, Nature Medicine March 2026 (AI-delivered CBT quality evaluation); Headspace Ebb employer deployment data Dec 2025 (BusinessWire); JMIR Mental Health 2022 systematic review of Headspace RCTs (Linardon et al.); Flourish internal: Villanova/SMU/UCNJ/Foothill/Jackson College/UC Berkeley, VA grant BAA 36C10X24R0053, ROI two-pager, conference pipeline data.